Moreover, since we demonstrated the importance of Notch3 in T-ALL progression36, confirming the same role observed also in solid tumors63,64, we can speculate that Juglone-dependent Notch3 inhibition could be useful also for tumors that do not depend on Notch3 at their onset but that could recur and become more aggressive subsequently, due to a selective growth advantage represented by the Notch3-dependent UPR maintenance. The gene discussed is NOTCH3; the disease is acute lymphoblastic leukemia.